Dr. Lal PathLabs (LALPATHLAB) Q4 2025 earnings summary

Executive summary

• Achieved 10.5% revenue growth in FY25, outpacing industry estimates, driven by volume expansion, deeper market penetration, and no price hikes.

• PAT rose 81.4% in Q4 FY25 and 35.9% in FY25, with a one-time deferred tax benefit from Suburban Diagnostics integration.

• Expanded network to 298 labs and 6,607 patient service centers, focusing on Tier 3/4 towns and core geographies.

• Swasthfit bundled test program contributed 24% of FY25 revenue, up from 22% in FY24.

• Major digital transformation completed, including unified IT infrastructure and advanced laboratory information systems.

Financial highlights

• FY25 consolidated revenue: INR 25,548 million (up from INR 22,958 million); Q4 FY25 revenue: INR 6,284 million (up from INR 5,638 million).

• FY25 consolidated net profit: INR 4,922 million (up from INR 3,623 million); Q4 FY25 net profit: INR 1,555 million (up from INR 858 million).

• FY25 standalone revenue: INR 24,631 million; standalone net profit: INR 4,973 million.

• FY25 EBITDA: INR 6,960 million (margin 28.3%); Q4 FY25 EBITDA: INR 1,690 million (margin 28.1%).

• EPS for FY25: INR 58.5 (standalone INR 59.7); total dividend for FY25: INR 24 per share (240%).

Outlook and guidance

• FY26 revenue growth expected at 11-12%, driven by volume and revenue per patient growth.

• EBITDA margin guidance for FY26 at ~27%, reflecting investments in new geographies, talent, and digital initiatives.

• No immediate plans for price increases; pricing strategy remains strategic.

• Focus on expanding in Tier 3/4 markets and strengthening core Tier 1/metro presence.

• Confident in funding growth through strong net cash and internal accruals.